TRACON Pharmaceuticals (NASDAQ:TCON) Given “Neutral” Rating at HC Wainwright

TRACON Pharmaceuticals (NASDAQ:TCON)‘s stock had its “neutral” rating reiterated by equities researchers at HC Wainwright in a research report issued on Monday, Benzinga reports.

Separately, StockNews.com lowered TRACON Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday.

TRACON Pharmaceuticals Stock Performance

Shares of NASDAQ:TCON traded down $0.16 during midday trading on Monday, reaching $1.44. The company had a trading volume of 230,227 shares, compared to its average volume of 191,963. The company has a fifty day simple moving average of $1.50 and a two-hundred day simple moving average of $3.42. The firm has a market cap of $3.86 million, a price-to-earnings ratio of 2.19 and a beta of 1.28. TRACON Pharmaceuticals has a 1-year low of $0.66 and a 1-year high of $14.75.

TRACON Pharmaceuticals (NASDAQ:TCON) last released its earnings results on Tuesday, May 14th. The biopharmaceutical company reported ($1.33) earnings per share for the quarter, missing the consensus estimate of ($1.20) by ($0.13). The firm had revenue of $0.10 million for the quarter. During the same period in the prior year, the company earned ($7.20) EPS. Analysts expect that TRACON Pharmaceuticals will post -4 EPS for the current year.

TRACON Pharmaceuticals Company Profile

TRACON Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel targeted therapeutics for cancer in the United States. Its clinical stage products include envafolimab (KN035), a PD-L1 single-domain antibody for the treatment of refractory soft tissue sarcoma; and YH001, an investigational humanized cytotoxic T-lymphocyte-associated protein 4 IgG1 monoclonal antibody that is in Phase I clinical trial for the treatment of various cancer indications.